Background: Small renal masses are increasingly being discov-
Results:
We identified no clinical trials in the literature. Thus we described the results from case series and retrospective studies with a reasonable sample size (number of reported patients in each study > 65). Most patients undergoing RFA had T1a disease with a mean tumour size of about 3 cm. Radiofrequency ablation was usually performed percutaneously with image guidance. Reported follow-up was short and ranged from 1 to 30 months. Most series used radiographic response as a surrogate for cancer control. The rates of local recurrence of the tumour were as high as 13.0% (average 8.5%) and were slightly higher than those associated with cryoablation and partial nephrectomy. Complications included hemorrhage, ureteral strictures and loss of a renal unit.
Conclusion:
Our review demonstrates that RFA is a suitable and promising therapy in patients with small renal tumours who are considered to be poor candidates for more involved surgery. However, clinical trials with long-term data are needed to establish the oncological efficacy.
Introduction
In Canada, the incidence of renal cancer is 4500 new cases per year, with 1500 patients dying of the disease. 1 Small renal masses are increasingly being discovered incidentally on imaging performed for another reason. [2] [3] [4] The natural history of these incidentally discovered masses remains unclear. When surgically excised, 70%-80% are proven to be renal cell carcinomas and the rest are benign. [5] [6] [7] [8] When technically feasible, the standard of care for these masses has been partial nephrectomy. Local and distant oncological control has been well established with surgical excision. 9 In the last 10 years, a minimally invasive approach with laparoscopy has largely supplanted open surgery. The question of whether in situ ablative technologies 10 12, 13 Several ablative technologies have been investigated, including cryoablation (CA), radiofrequency ablation (RFA), microwave, 14 high-intensity focused ultrasonography, 15, 16 laser interstitial thermotherapy, 17 microwave thermotherapy and radiosurgery.
Radiofrequency ablation is a minimally invasive treatment for localized cancer in which a small needle attached to a device that delivers radiofrequency energy is inserted into a tumour to destroy the cancerous tissue while the patient is sedated or under general anesthesia. The procedure is usually performed percutaneously with image guidance using computed tomography (CT) or ultrasonography and the tumour is destroyed by heating to temperatures exceeding 60ºC. 18 Radiofrequency ablation has been licensed by Health Canada and used for many years in the treatment of cardiac abnormalities, trigeminal neuralgia and osteoid osteomas; more recently, it has been used in the treatment of neoplasms in the liver, kidney, prostate, bone and soft tissues, and other areas. 19 The role of RFA in the treatment of renal neoplasms is still being investigated with several series reporting short-term outcomes.
We sought to examine the state of knowledge of RFA in the treatment of renal tumours. We reviewed the efficacy of this technology in terms of oncological control and prevention of local recurrence and metastasis. We also examined complications and safety concerns as they relate to RFA.
Methods
There was no language restriction. We obtained stud- We searched the databases using a comprehensive search strategy for kidney cancer and RFA using medical subject headings (MeSH) and key words, including an exhaustive list of synonyms (Appendix 1). We adapted the search strategy for each database to achieve more sensitivity. We also examined the bibliographic references in relevant review articles for eligible trials.
We were interested in the following clinical outcome measurements: cancer specific survival, radiographic success, tumour recurrence, local tumour progression or distant metastases, need for repeat ablation, complications, adverse events reported and renal function.
Results
Our search in the electronic databases identified 1428 titles. After screening by title and then abstract, we obtained full paper copies for 71 studies that were potentially eligible for inclusion in the review. Of these, we did not identify any randomized controlled trials. We identified several case series and retrospective studies and 1 controlled clinical trial. Thus we included the case series and retrospective studies with a reasonable sample size (n > 65), and the controlled clinical trial in our review. Table 1 summarizes the characteristics of published studies on RFA. Most patients undergoing RFA had T1a disease with a mean tumour size of about 3 cm. RFA was usually carried out percutaneously with image guidance. However, if the tumour was endophytic or otherwise not accessible percutaneously, laparoscopy could be carried out to expose the kidney and the tumour. Reported follow-up was short and ranged from 1 to 30 months. Table 2 outlines the clinical outcomes and complications reported in the RFA studies we examined. Most series used radiographic response as a surrogate for cancer control. We considered lack of contrast enhancement, decrease in size of the tumour or lack of growth on serial imaging to be signs of complete and successful ablation. The rates of local recurrence of the tumour were as high as 13.0% (average 8.5%) and were slightly higher than those associated with cryoablation and partial nephrectomy.
Although RFA is generally well tolerated with a favourable complication profile, it is not an innocuous procedure. Serious complications can occur, including hemorrhage, ureteral strictures and loss of a renal unit.
Discussion
The goal of RFA is to destroy tissue by heat using radiofrequency energy. The procedure involves delivering an alternating electrical current at high frequency causing agitation of ions, which in turn results in heat. It has been shown that heating tissue to 55°-60°C for 5 minutes results in irreversible Radiofrequency ablation for small renal masses cellular damage, and heating to more than 70°C causes cell death and tissue coagulation. 33, 34 Temperature-based RFA machines (e.g., RITA Medical Systems, Inc.) use temperatures as high as 105°C during treatment. One drawback to RFA is that, unlike cryoablation, it is not possible to monitor the ablated area via imaging in real time. It is therefore difficult to ensure that the entire surface area of a tumour receives the same amount of heat.
Our review demonstrates that although promising, the evidence behind RFA remains immature. Prospective and randomized trials are lacking. Reported follow-up is too short, with most studies reporting a follow-up of 2 years or less and all studies reporting a follow-up less than 3 years. The natural history of small renal masses is not well defined, but one review demonstrated a growth rate of 0.28 cm/year with a metastatic rate of 1% after 34 months of follow-up. 35 This seems to indicate that the reported follow-up for most RFA series is too short to draw any meaningful conclusions about oncological efficacy.
Most RFA studies equate a successful ablation with radiological response. However, imaging changes after RFA are not always predictable. El Dib et al. 
Conclusion
This review demonstrates that RFA is a suitable and promising therapy in patients with small renal tumours (< 4 cm) who are considered to be poor candidates for more involved surgery. Long-term data on oncological control is lacking. Longer follow-up and more rigorous head-to-head trials Radiofrequency ablation for small renal masses 
